UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 232

Sortiert nach

Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer

Vaccines (Basel), 2021-11, Vol.9 (12), p.1413

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine

Expert review of vaccines, 2024, Vol.23 (1), p.283-293

2024

Link zum Volltext

Verfügbarkeit prüfen

Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges

Expert review of vaccines, 2020-02, Vol.19 (2), p.133-142

2020

Link zum Volltext

Verfügbarkeit prüfen

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

The New England journal of medicine, 2015-02, Vol.372 (8), p.711-723

2015

Link zum Volltext

Verfügbarkeit prüfen

COVID-19 vaccine strategies must focus on severe disease and global equity

The Lancet (British edition), 2022-01, Vol.399 (10322), p.406-410

2022

Link zum Volltext

Verfügbarkeit prüfen

The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection

Expert review of vaccines, 2016-07, Vol.15 (7), p.795-798

2016

Link zum Volltext

Verfügbarkeit prüfen

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

The New England journal of medicine, 2012-04, Vol.366 (14), p.1275-1286

2012

Link zum Volltext

Verfügbarkeit prüfen

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

The New England journal of medicine, 2012-04, Vol.366 (14), p.1275-1286

2012

Link zum Volltext

Verfügbarkeit prüfen

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

PLoS medicine, 2020-02, Vol.17 (2), p.e1003038

2020

Link zum Volltext

Verfügbarkeit prüfen

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

Proceedings of the National Academy of Sciences - PNAS, 2013-05, Vol.110 (22), p.9019-9024

2013

Link zum Volltext

Verfügbarkeit prüfen

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines

Science translational medicine, 2014-03, Vol.6 (228), p.228ra38

2014

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand

The Journal of infectious diseases, 2006-12, Vol.194 (12), p.1661-1671

2006

Link zum Volltext

Verfügbarkeit prüfen

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Immunity (Cambridge, Mass.), 2013-01, Vol.38 (1), p.176-186

2013

Link zum Volltext

Verfügbarkeit prüfen

A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand

Human vaccines & immunotherapeutics, 2019-10, Vol.15 (10), p.2440-2445

2019

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity and Safety of a 9-Valent HPV Vaccine

Pediatrics (Evanston), 2015-07, Vol.136 (1), p.e28

2015

Link zum Volltext

Verfügbarkeit prüfen

Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease

Cancer epidemiology, biomarkers & prevention, 2014-10, Vol.23 (10), p.1997-2008

2014

Link zum Volltext

Verfügbarkeit prüfen

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques

PLoS pathogens, 2015-08, Vol.11 (8), p.e1005042-e1005042

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 232

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(190)
Mit Volltextzugriff
(213)

Publikationsform

Artikel
(232)

Sprache

Englisch
(232)
Japanisch
(26)

Erscheinungsjahr

n.n

Thema

Science & Technology
(172)
Humans
(160)
Life Sciences & Biomedicine
(158)
Infectious Diseases
(89)
Female
(88)
Vaccines
(84)
Male
(82)
Adult
(73)
Immunology
(73)
Hiv
(63)
Aids Vaccines - Immunology
(56)
Thailand
(56)
Hiv Infections - Prevention & Control
(55)
Human Immunodeficiency Virus
(55)
Hiv-1 - Immunology
(50)
Biological And Medical Sciences
(49)
Virology
(44)
Aids
(42)
Medical Sciences
(41)
Hiv Infections - Immunology
(39)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer

Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine

Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

COVID-19 vaccine strategies must focus on severe disease and global equity

The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection

Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial

Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family

HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities

A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand

Immunogenicity and Safety of a 9-Valent HPV Vaccine

Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144

Suchergebnisse filtern